Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PDS Biotechnology Corporation (PDSB : NSDQ)
 
 • Company Description   
PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary Versamune(R) platform technology, which activates and directs the human immune system. PDS Biotechnology Corp, formerly known as Edge Therapeutics Inc., is based in Berkeley Heights, United States.

Number of Employees: 24

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.22 Daily Weekly Monthly
20 Day Moving Average: 518,764 shares
Shares Outstanding: 45.71 (millions)
Market Capitalization: $55.77 (millions)
Beta: 1.21
52 Week High: $4.42
52 Week Low: $0.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.26% -23.19%
12 Week 30.47% 4.89%
Year To Date -25.15% -28.97%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
303A College Road
-
East Princeton,NJ 08540
USA
ph: 800-208-3343
fax: 908-790-1212
mmoyer@lifesciadvisors.com http://www.pdsbiotech.com
 
 • General Corporate Information   
Officers
Frank Bedu-Addo - Chief Executive Officer; President and Director
Lars Boesgaard - Chief Financial Officer
Gregory Freitag - Director
Stephen Glover - Director
Richard Sykes - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 70465T107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 45.71
Most Recent Split Date: 3.00 (0.05:1)
Beta: 1.21
Market Capitalization: $55.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.49
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -150.59
12/31/24 - -137.88
ROA
06/30/25 - -
03/31/25 - -69.15
12/31/24 - -66.18
Current Ratio
06/30/25 - -
03/31/25 - 2.33
12/31/24 - 2.64
Quick Ratio
06/30/25 - -
03/31/25 - 2.33
12/31/24 - 2.64
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.49
12/31/24 - 0.51
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.29
12/31/24 - 0.49
Debt-to-Capital
06/30/25 - -
03/31/25 - 22.25
12/31/24 - 32.78
 

Powered by Zacks Investment Research ©